Dostarlimab

• Description:

  Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively[1].

• Product Name Alternative:

  TSR-042; ANB-011; WBP-285

• UNSPSC:

  12352203

• Target:

  PD-1/PD-L1

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/dostarlimab.html

• Purity:

  98.92

• Solubility:

  H2O

• Smiles:

  [Dostarlimab]

• Molecular Weight:

  (144.18 kDa)

• References & Citations:

  [1]Kumar S, et al. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models. MAbs. 2021 Jan-Dec;13 (1) :1954136.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Launched

• CAS Number:

  [2022215-59-2]